$695 | Single User
$1395 | Global License

Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?

Published by FirstWord Pharma: 22 Jul 2014 | 139 | In Stock

Introduction

Scope



Although the clinical promise of cancer immunotherapies looks poised to see these products gain a dominant foothold in the oncology market for decades to come, developers of alternative cancer treatments will be hoping to carve out their own share of revenues – most feasibly by targeting subsets of patient populations.


One such opportunity exists in the malignant melanoma market, where between 40 percent and 50 percent of patients are diagnosed with the V600 BRAF mutation.


Roche – the recognised global leader in personalised cancer medicine – was the first to develop a marketed therapy to specifically treat these patients; approved in 2011, the Swiss company had previously in-licensed the BRAF inhibitor Zelboraf from Plexxikon in 2006.


Zelboraf became the first new therapy for malignant melanoma to be approved by the FDA for many years. Its route to market was accelerated not only by the poor prognosis and median survival time (less than a year) among these patients, but development alongside a companion diagnostic from Roche that helped to both shorten clinical trial programmes and define relevant patients. In Phase III studies, Zelboraf demonstrated a median progression-free survival (PFS) of 5.3 months (versus 1.6 months for dacarbazine).


Earlier this week, Roche announced that Phase III studies of Zelboraf in combination with a second therapy – the MEK inhibitor cobimetinib (being co-developed with Exelixis) – had delivered positive top-line data versus Zelboraf alone. With regulatory filings expected later this year, approval for the combination is earmarked for the second half of 2015. See ViewPoints: Roche sets up face-off with Novartis via positive melanoma data.


In the meantime, however, GlaxoSmithKline is already marketing its own combination of MEK and BRAF inhibitors (Mekinist and Tafinlar), which was approved by the FDA in January, and is in the process of being sold to Novartis (along with the remainder of GlaxoSmithKline's oncology pipeline – see ViewPoints: GlaxoSmithKline, Novartis embrace home comforts via innovative billion deal).


Phase III data supporting the use of Mekinist and Tafinlar has its limitations (the COMBI-d study demonstrated PFS of 9.3 months), but based on prescription data the combination appears to be gaining notable traction among oncologists in the US, according to analysts at Bloomberg Industries.


There is some expectation that the data for Roche's combination will be superior (Phase I data delivered PFS of 13.7 months), but with launch at least a year away, GlaxoSmithKline (and shortly Novartis) have time to push home their first-to-market advantage.


If the arrival of Roche's combination is one future dynamic in the BRAF V600 melanoma space, the other is the potential future treatment of patients with immunotherapy, possibly led by a combination of Bristol-Myers Squibb's already approved Yervoy franchise with its late-stage PD-1 inhibitor nivolumab. Will small molecular targeted therapies retain a significant presence in the long term?


Puchase Reasons


In light of these dynamics – and the clinical update regarding Roche's combination this week – FirstWord is polling US-based oncologists to assess their current treatment choices for BRAF V600 mutation-positive melanoma. Specifically we are asking them...


  • What percentage of advanced melanoma patients are currently tested for the BRAF V600 mutation?

  • Which therapy – or combination – they use most frequently to treat BRAF V600 mutation-positive melanoma patients?

  • Which therapy – or combination – they expect to be using most frequently in 12 months time?

  • What factor – if any – has prevented them from using the Mekinist/Tafinlar combination?

  • Whether they expect immunotherapies to assume a dominant first- or second-line position in the future treatment paradigm?
  • Table of Contents
    for Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    139 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients? | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...

    • Allied Market Research
    • CBR Pharma
    • Current Partnering
    • Firstword
    • Global Data
    • Global Markets Direct
    • ICD Research
    • Infinti Research Technavio
    • Marketline
    • Markets and Markets
    • Micro Markets Monitor
    • MP Advisors
    • Venture Planning Group
    • GMR Data